VivoSeq
Other

Resectable NSCLC

0

Pipeline Programs↗

13

Active Trials↗

2

Companies Involved↗

Resectable NSCLC is an early-stage landscape with 0 programs across 2 companies. The most active players are AstraZeneca, Regeneron.

Intelligence

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

60/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

0 programs

PreclinicalRegeneron logo

Regeneron

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

21

clinical trials

Recruiting6 · 29%
Active, not recruiting4 · 19%
Not yet recruiting3 · 14%
Completed3 · 14%
Unknown status3 · 14%
Withdrawn1 · 5%
Other1 · 5%

Clinical Trials

Trial Activity

21 trials

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
Recruiting·AstraZeneca logoAstraZeneca·Phase 3·NCT05211895·860 enrolled
Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC
Recruiting·—·Phase 2·NCT06467617·35 enrolled
A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC
Recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT04316364·537 enrolled
Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)
Recruiting·TThe First Affiliated Hospital of Guangzhou Medical University·Phase 2·NCT06926790·69 enrolled
Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC
Recruiting·—·Phase 2·NCT06897046·90 enrolled
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
Recruiting·IIcahn School of Medicine at Mount Sinai·Phase 1/2·NCT06088771·21 enrolled
Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC
Active, not recruiting·SShanghai Junshi Bioscience Co., Ltd.·Phase 3·NCT04158440·501 enrolled
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
Active, not recruiting·Regeneron logoRegeneron·Phase 2·NCT03916627·65 enrolled
To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations
Active, not recruiting·AstraZeneca logoAstraZeneca·Phase 2·NCT06194448·76 enrolled
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC
Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT02259621·39 enrolled
Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC
Not yet recruiting·XXuanwu Hospital, Beijing·N/A·NCT06607926·40 enrolled
Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC
Not yet recruiting·TTang-Du Hospital·Phase 2·NCT06475755·178 enrolled
A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC
Not yet recruiting·YYang Fan, MD·Phase 2·NCT07086326·164 enrolled
Intratumoral Cisplatin for Resectable NSCLC
Completed·UUniversity of Vermont·Phase 1·NCT04809103·6 enrolled
Toripalimab Combined With Double Platinum-based Chemotherapy for Initially Unresectable NSCLC
Completed·—·Phase 2·NCT04144608·40 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)